Cancer Clinical Trials: Proactive Strategies (Cancer Treatment and Research Book 132)

Foreword written by Samuel A. Wells, Jr., MDProfessor of SurgeryDuke University Medical Center, Durham, NC According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with solid cancer every year. About 50% of them will be potentially cured by surgery. The other half of the population may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Therefore, cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Likewise, adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection of their cancer. Only about 3-5% of the adult cancer patients are enrolled in clinical trials. When the pediatric cancer clinical trial groups were able to accrue over 40 percent of eligible patients to their clinical trials, significant impact was made on the survival of these pediatric cancer patients. However, multiple barriers exist to block adult cancer patients from entering into clinical protocols. The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited. __"Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application."__ __Steven T. Rosen, M.D.Series Editor__ Foreword written by Samuel A. Wells, Jr., MD Professor of Surgery Duke University Medical Center, Durham, NC According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with solid cancer every year. About 50% of them will be potentially cured by surgery. The other half of the population may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Therefore, cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Likewise, adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection of their cancer. Only about 3-5% of the adult cancer patients are enrolled in clinical trials. When the pediatric cancer clinical trial groups were able to accrue over 40 percent of eligible patients to their clinical trials, significant impact was made on the survival of these pediatric cancer patients. However, multiple barriers exist to block adult cancer patients from entering into clinical protocols. The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited. "Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application." Steven T. Rosen, M.D. Series Editor Front Matter....Pages i-xix Historical Perspective and Evolving Concerns for Human Research....Pages 1-10 Cancer Trials and the Institutional Review Board (IRB)....Pages 11-30 NCI’s Cancer Therapy Evaluation Program: A Commitment to Treatment Trials....Pages 31-50 The Role of the FDA in Cancer Clinical Trials....Pages 51-109 The Role of Cooperative Groups in Cancer Clinical Trials....Pages 111-129 The Advocate Role in Clinical Study Development and Partnering with Patient Advocates in Your Local Institution....Pages 131-141 The National Breast Cancer Coalition: Setting the Standard for Advocate Collaboration in Clinical Trials....Pages 143-156 The Role of the Principal Investigator in Cancer Clinical Trials....Pages 157-177 The Audit Process and How to Ensure a Successful Audit....Pages 179-197 The Privacy Rule (HIPAA) as it Relates to Clinical Research....Pages 199-207 The Commission on Cancer, American College of Surgeons’ Response to HIPAA....Pages 209-217 Ethical and Legal Issues in the Conduct of Cancer Clinical Trials....Pages 219-229 The Role of the Office of Research Integrity in Cancer Clinical Trials....Pages 231-239 Strategies for the Administration of a Clinical Trials Infrastructure: Lessons from a Comprehensive Cancer Center....Pages 241-274 The Clinical Research Process: Building a System in Harmony with its Users....Pages 275-290 Cancer Research and Clinical Trial in Action: An Important Exercise Before You Embark on Your Study....Pages 291-309 Back Matter....Pages 311-319 According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with cancer every year. Fifty percent of them will be cured by surgery; the remaining 50% may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection. Only about 3-5% of the eligible adult patients are enrolled in clinical trials. When pediatric cancer clinical trial groups accrued over 40% of eligible patients to their clinical trials, significant impact was made on survival of these patients. However, multiple barriers block adult patients from entering into clinical protocols Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application. The book has a foreword by Samuel A. Wells, Jr., MD, Professor of Surgery, Duke University Medical Center, Durham, NC, former Director of the American College of Surgeons and Founder of the American College of Surgeons Oncology Group.

clinical Trials Remain The Most Important Vehicle For Improving The Care Of Cancer Patients. This Text Presents The Fundamental Components And Challenges Involving Clinical Investigations. Leading Experts Discuss The Critical Issues Covering The Spectrum Of Important Topics From Planning To Application.